Table 6

MTHFR diplotypes and breast cancer survival

HR (95% CI)1

p-value


MTHFR diplotypes (n = 198)2

CC/AA + CC/AC (high enzyme activity)

1

Others (low enzyme activity)

0.61 (0.3–1.22)

0.16

ER-negative (n = 84)

CC/AA + CC/AC

1

Others

0.47 (0.19–1.20)

0.11

ER-positive (n = 114)

CC/AA + CC/AC

1

Others C

0.83 (0.27–2.59)

0.75

African-American (n = 121)

CC/AA + CC/AC

1

Others

0.22 (0.05–0.96)

0.04

Caucasian (n = 77)

CC/AA + CC/AC

1

Others

1.19 (0.36–3.96)

0.78

No Chemotherapy (n = 81)

CC/AA + CC/AC

1

Others

0.54 (0.15–1.96)

0.35

Chemotherapy (n = 117)

CC/AA + CC/AC

1

Others

0.59 (0.25–1.38)

0.23


1 Cox Proportional-Hazards regression with adjustments for age at diagnosis, race, BMI, estrogen receptor, TNM stage, and chemotherapy. Time at risk and number of events for the strata are shown in Tables 4 and 5.

2 MTHFR diplotypes were generated from the C677T and A1298C genotypes using the information shown in Table 3. Diplotypes were dichotomized into a group that encodes a high activity enzyme [CC(677) and AA or AC(1298)] and a group that encodes a low activity enzyme (all other diplotypes).

Martin et al. BMC Cancer 2006 6:257   doi:10.1186/1471-2407-6-257

Open Data